<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="237">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158062</url>
  </required_header>
  <id_info>
    <org_study_id>SaINT-ov02</org_study_id>
    <nct_id>NCT05158062</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer</brief_title>
  <official_title>Phase II Study of Pembrolizumab and Bevacizumab in Combination With Platinum-based Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Patients With Platinum-sensitive Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kosei Hasegawa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saitama Medical University International Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicenter, single-arm, phase II study evaluating the efficacy of&#xD;
      pembrolizumab and bevacizumab in combination with platinum-based chemotherapy (PBC) followed&#xD;
      by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with&#xD;
      platinum-sensitive recurrent ovarian cancer.This study is planned to enroll eligible 35&#xD;
      patients from multiple study sites in Japan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year progression-free survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>Two-year progression-free survival rate after administration of pembrolizumab and bevacizumab in combination with PBC followed by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer based on RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>PFS after administration of the study treatment based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in maintenance period by chemotherapy responder</measure>
    <time_frame>3 years</time_frame>
    <description>PFS in maintenance period in patients who assessed CR or PR at last tumor assessment before entering maintenance period based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>ORR after administration of the study treatment based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <description>DCR after administration of the study treatment based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>3 years</time_frame>
    <description>DOR after administration of the study treatment based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year progression-free survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>One-year progression-free survival rate after administration of the study treatment based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>OS after administration of the study treatment using Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>The number and proportion of participants with adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>3 years</time_frame>
    <description>Exploratory assessment of relationship between biomarkers and efficacy endpoints if possible</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Carcinoma, Ovarian Epithelial</condition>
  <arm_group>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>pembrolizumab 200 mg every three weeks (Q3W)</description>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olaparib</intervention_name>
    <description>olaparib 300 mg twice daily (BID) during maintenance period</description>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
    <other_name>LYNPARZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>bevacizumab 15 mg/kg Q3W</description>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
    <other_name>AVASTIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin AUC=5 or 6 Q3W during treatment period</description>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel 175 mg/m2 Q3W during treatment period</description>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel 60 ~ 70 mg/m2 Q3W during treatment period</description>
    <arm_group_label>pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is at least 20 years of age on the day of signing informed consent with&#xD;
             histologically confirmed epithelial ovarian cancer (excluding borderline ovarian&#xD;
             tumor) excluding mucinous carcinoma.&#xD;
&#xD;
          2. Participant has received only one regimen of PBC (3 cycles or more) as prior therapy&#xD;
             with clinical CR (determined by negative clinical examination and a normal CA-125&#xD;
             level).&#xD;
&#xD;
          3. Participant has documentation of progressive disease at least 6 months from completion&#xD;
             of PBC (platinum-sensitive).&#xD;
&#xD;
          4. Participant with measurable disease based on RECIST 1.1 at screening&#xD;
&#xD;
          5. Participant is able to provide a core or excisional biopsy of a tumor for testing of&#xD;
             PD-L1 status, etc.&#xD;
&#xD;
          6. Participant with Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1 at the&#xD;
             screening&#xD;
&#xD;
          7. Participant has a life expectancy of at least 12 weeks as determined by the&#xD;
             investigators.&#xD;
&#xD;
          8. Participant has adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A Women of Childbearing Potential (WOCBP) who has a positive urine pregnancy test at&#xD;
             screening. If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
             pregnancy test will be required.&#xD;
&#xD;
          2. Participant has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2&#xD;
             agent or with an agent directed to another stimulatory or co-inhibitory T-cell&#xD;
             receptor (eg, CTLA-4, OX-40, CD137).&#xD;
&#xD;
          3. Participant has received prior systemic anti-cancer therapy including investigational&#xD;
             agents within 4 weeks prior to the first dose of study drug.&#xD;
&#xD;
          4. Participant has received prior radiotherapy within 2 weeks of the first dose of study&#xD;
             drug.&#xD;
&#xD;
          5. Participant has received major surgery within 4 weeks prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          6. Participant has received a live vaccine or live-attenuated vaccine within 30 days&#xD;
             prior to the first dose of study drug. Administration of killed vaccines is allowed.&#xD;
&#xD;
          7. Participant is currently participating in or has participated in a study of an&#xD;
             investigational agent or has used an investigational device within 4 weeks prior to&#xD;
             the first dose of study drug.&#xD;
&#xD;
          8. Participant has a diagnosis of immunodeficiency or is receiving chronic systemic&#xD;
             steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          9. Participant has a known additional malignancy that is progressing or has required&#xD;
             active treatment within the past 3 years.&#xD;
&#xD;
         10. Participant has known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
         11. Participant has severe hypersensitivity (≥Grade 3) to the study treatment and/or any&#xD;
             of its excipients.&#xD;
&#xD;
         12. Participant has active autoimmune disease that has required systemic treatment in the&#xD;
             past 2 years (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs).&#xD;
&#xD;
         13. Participant has a history of (non-infectious) pneumonitis/interstitial lung disease&#xD;
             that required treatment with steroids or has current pneumonitis/interstitial lung&#xD;
             disease.&#xD;
&#xD;
         14. Participant has an active infection requiring systemic therapy.&#xD;
&#xD;
         15. Participant has a known history of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
         16. Participant has a known history of Hepatitis B (defined as Hepatitis B surface antigen&#xD;
             [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative]&#xD;
             is detected) infection.&#xD;
&#xD;
         17. Participant has received colony-stimulating factors (granulocyte colony stimulating&#xD;
             factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or&#xD;
             recombinant erythropoietin) within 2 weeks prior to the first dose of study drug.&#xD;
&#xD;
         18. Participant has clinically serious cardiovascular/cerebrovascular diseases (eg,&#xD;
             cerebrovascular accident/stroke [less than 6 month prior to enrollment], myocardial&#xD;
             infarction [less than 6 month prior to enrollment], uncontrolled and potentially&#xD;
             reversible cardiac conditions [unstable ischemia, uncontrolled symptomatic arrhythmia,&#xD;
             congestive heart failure, QTcF prolongation &gt;500 msec, electrolyte disturbances,&#xD;
             hypertension defined as systolic &gt;150 mmHg or diastolic &gt;90 mmHg etc.] or participant&#xD;
             has congenital long QT syndrome).&#xD;
&#xD;
         19. Participant has known abdominal fistula, gastrointestinal fistula or gastrointestinal&#xD;
             perforation and/or higher risks of bleeding.&#xD;
&#xD;
         20. Participant has either myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or&#xD;
             has features suggestive of MDS/AML.&#xD;
&#xD;
         21. Participant is currently receiving either strong (eg, itraconazole, telithromycin,&#xD;
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,&#xD;
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin,&#xD;
             erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450&#xD;
             (CYP)3A4 that cannot be discontinued prior to the first dose of study drug.&#xD;
&#xD;
         22. Participant is currently receiving either strong (eg, phenobarbital, enzalutamide,&#xD;
             phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine, and St&#xD;
             John's Wort) or moderate (eg, bosentan, efavirenz, modafinil) inducers of CYP3A4 that&#xD;
             cannot be discontinued prior to the first dose of study drug.&#xD;
&#xD;
         23. Participant is either unable to swallow orally administered medication or has a&#xD;
             gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel&#xD;
             obstruction, malabsorption).&#xD;
&#xD;
         24. Participant has known psychiatric or substance abuse disorders that would interfere&#xD;
             with cooperation with the requirements of the trial.&#xD;
&#xD;
         25. Participant is pregnant or breastfeeding or expecting to conceive or father children&#xD;
             within the projected duration of the study, starting with the screening visit through&#xD;
             210 days after the last dose of study treatment.&#xD;
&#xD;
         26. Participant has had an allogenic tissue/solid organ transplant.&#xD;
&#xD;
         27. Participant has a history or current evidence of any condition, therapy, or laboratory&#xD;
             abnormality that might confound the results of the study, interfere with the&#xD;
             participant's participation for the full duration of the study, or is not in the best&#xD;
             interest of the participant to participate, in the opinion of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kosei Hasegawa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saitama Medical University International Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kosei Hasegawa, MD, PhD</last_name>
    <phone>+81-42-984-4111</phone>
    <phone_ext>5627</phone_ext>
    <email>koseih@saitama-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miwa Hirai</last_name>
    <phone>+81-3-6779-8222</phone>
    <email>saint-ov02@cmic.co.jp</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Saitama Medical University International Medical Center</investigator_affiliation>
    <investigator_full_name>Kosei Hasegawa</investigator_full_name>
    <investigator_title>Professor and Director, Department of Gynecologic Oncology</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer, pembrolizumab, olaparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

